$AGIO
Agios Pharmaceuticals Inc

2015 Q2 Form 10-Q Financial Statement

#000119312515181968 Filed on May 11, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $13.22M $34.20M $8.411M
YoY Change 57.16% 306.63% 34.19%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.930M $6.950M $3.290M
YoY Change 114.15% 111.25% 77.84%
% of Gross Profit
Research & Development $36.42M $32.44M $17.41M
YoY Change 61.34% 86.38% 51.87%
% of Gross Profit
Depreciation & Amortization $800.0K $370.0K $332.0K
YoY Change 100.0% 11.45% -4.87%
% of Gross Profit
Operating Expenses $45.35M $39.40M $20.70M
YoY Change 69.6% 90.37% 55.44%
Operating Profit -$32.13M -$5.195M -$12.28M
YoY Change 75.3% -57.71% 74.34%
Interest Expense $240.0K $240.0K $40.00K
YoY Change 700.0% 500.0% 300.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$31.90M -$4.960M -$12.25M
YoY Change 74.36% -59.5% 74.03%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$31.90M -$4.957M -$12.25M
YoY Change 74.34% -59.53% 69.45%
Net Earnings / Revenue -241.3% -14.49% -145.62%
Basic Earnings Per Share -$0.39
Diluted Earnings Per Share -$854.5K -$133.3K -$0.39
COMMON SHARES
Basic Shares Outstanding 37.30M shares 37.22M shares 31.59M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $369.8M $344.7M $162.3M
YoY Change 55.06% 112.43% 40.13%
Cash & Equivalents $72.53M $35.26M $32.84M
Short-Term Investments $297.3M $309.5M $129.4M
Other Short-Term Assets $4.600M $5.500M $7.500M
YoY Change -30.3% -26.67% 188.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $390.2M $364.1M $172.4M
YoY Change 59.14% 111.2% 45.75%
LONG-TERM ASSETS
Property, Plant & Equipment $19.33M $14.30M $3.452M
YoY Change 502.12% 314.17% -15.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $64.20M $95.30M $5.000M
YoY Change 184.07% 1806.0%
Other Assets $660.0K $640.0K $467.0K
YoY Change 45.05% 37.04% -86.26%
Total Long-Term Assets $84.23M $110.2M $9.495M
YoY Change 213.51% 1060.56% 24.93%
TOTAL ASSETS
Total Short-Term Assets $390.2M $364.1M $172.4M
Total Long-Term Assets $84.23M $110.2M $9.495M
Total Assets $474.4M $474.3M $181.9M
YoY Change 74.39% 160.75% 44.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.914M $12.64M $4.411M
YoY Change 65.44% 186.56% -6.15%
Accrued Expenses $11.58M $15.60M $3.841M
YoY Change 112.32% 306.25% 92.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $45.20M $36.38M $34.08M
YoY Change 1.25% 6.74% -7.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $25.00M $11.10M $3.000K
YoY Change 1249900.0% 369900.0% -99.99%
Total Long-Term Liabilities $25.00M $11.10M $3.000K
YoY Change 1249900.0% 369900.0% -99.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $45.20M $36.38M $34.08M
Total Long-Term Liabilities $25.00M $11.10M $3.000K
Total Liabilities $70.20M $47.50M $34.08M
YoY Change 57.26% 39.36% -61.57%
SHAREHOLDERS EQUITY
Retained Earnings -$203.8M -$171.9M -$125.7M
YoY Change 41.54% 36.77%
Common Stock $607.7M $598.5M $247.0M
YoY Change 76.4% 142.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $404.2M $426.8M $121.3M
YoY Change
Total Liabilities & Shareholders Equity $474.4M $474.3M $181.9M
YoY Change 74.39% 160.75% 44.49%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$31.90M -$4.957M -$12.25M
YoY Change 74.34% -59.53% 69.45%
Depreciation, Depletion And Amortization $800.0K $370.0K $332.0K
YoY Change 100.0% 11.45% -4.87%
Cash From Operating Activities $4.000M -$25.60M -$27.00M
YoY Change -463.64% -5.19% 125.0%
INVESTING ACTIVITIES
Capital Expenditures -$10.90M $3.797M $13.00K
YoY Change 10800.0% 29107.69% -95.27%
Acquisitions
YoY Change
Other Investing Activities $43.10M $48.80M -$12.30M
YoY Change -332.97% -496.75% -386.05%
Cash From Investing Activities $32.20M $45.00M -$12.30M
YoY Change -273.12% -465.85% -407.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.100M 1.800M 600.0K
YoY Change -98.84% 200.0%
NET CHANGE
Cash From Operating Activities 4.000M -25.60M -27.00M
Cash From Investing Activities 32.20M 45.00M -12.30M
Cash From Financing Activities 1.100M 1.800M 600.0K
Net Change In Cash 37.30M 21.20M -38.70M
YoY Change -50.53% -154.78% 383.75%
FREE CASH FLOW
Cash From Operating Activities $4.000M -$25.60M -$27.00M
Capital Expenditures -$10.90M $3.797M $13.00K
Free Cash Flow $14.90M -$29.40M -$27.01M
YoY Change -1590.0% 8.83% 120.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37298171 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32837000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4553028 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
35.94
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37289050 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
35.39
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1664398 shares
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
23 Securities
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37289050 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.42
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4203171 shares
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
598494000
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
641000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2370000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
426817000
CY2015Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2015Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2015Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
764000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
191000
CY2015Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1245000
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4000
CY2015Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
11007000
CY2015Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
195000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6886000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
12640000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15604000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171905000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
474336000
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
133000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
37000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
36379000
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
147926000
CY2015Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
404708000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
640000
CY2015Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
259635000
CY2015Q1 us-gaap Assets
Assets
474336000
CY2015Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
6906000
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
42700000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14297000
CY2015Q1 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
95258000
CY2015Q1 us-gaap Contracts Receivable Claims And Uncertain Amounts
ContractsReceivableClaimsAndUncertainAmounts
7000000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
364141000
CY2015Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
309450000
CY2015Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
7017000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
279052000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5512000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35256000
CY2015Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2015Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
404517000
CY2015Q1 agio One Time Receivable Eligibility Upon Dosing Of Last Patient Under First Split Licensed Program
OneTimeReceivableEligibilityUponDosingOfLastPatientUnderFirstSplitLicensedProgram
25000000
CY2015Q1 agio Potential Milestone Payment Receivable Upon Early Clinical Development Milestone Event
PotentialMilestonePaymentReceivableUponEarlyClinicalDevelopmentMilestoneEvent
22500000
CY2015Q1 agio Accrued Contracted Research And Development Costs Current
AccruedContractedResearchAndDevelopmentCostsCurrent
11829000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71560000
CY2013Q4 agio Extension Payment Receivable
ExtensionPaymentReceivable
20000000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3805420 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.19
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37100513 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
92 Securities
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37100513 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
591334000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
442000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5689000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
424366000
CY2014Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2014Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
549000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-57000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
310000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3724000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
35686000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11067000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14020000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-166948000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
491904000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2725000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
61089000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
453416000
CY2014Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
3841000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
590000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
107000
CY2014Q4 us-gaap Assets
Assets
491904000
CY2014Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
2334000
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
236900000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6386000
CY2014Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
125382000
CY2014Q4 us-gaap Contracts Receivable Claims And Uncertain Amounts
ContractsReceivableClaimsAndUncertainAmounts
6500000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
359546000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
328034000
CY2014Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
6492000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4814000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14031000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
360935000
CY2014Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
453473000
CY2014Q4 agio Extension Payment Receivable
ExtensionPaymentReceivable
20000000
CY2014Q4 agio Accrued Contracted Research And Development Costs Current
AccruedContractedResearchAndDevelopmentCostsCurrent
7340000
CY2010Q2 agio Discover Period Under Collaboration Agreement
DiscoverPeriodUnderCollaborationAgreement
P2Y
CY2010Q2 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2014-04
CY2010Q2 agio Agreement Amended Period
AgreementAmendedPeriod
2011-10
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
6000000
CY2014Q1 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
1500000
CY2013 agio Initial Agreement Period
InitialAgreementPeriod
P4Y
CY2013 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2015-04
CY2013 agio Date Of Extension Of Discovery Phase
DateOfExtensionOfDiscoveryPhase
2014-05
CY2013 agio Extended Agreement Period
ExtendedAgreementPeriod
P5Y
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M29D
CY2014 agio Initial Agreement Period
InitialAgreementPeriod
P5Y
CY2014 agio Receipt Due To Agreement Amendment
ReceiptDueToAgreementAmendment
20000000
CY2014 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2016-04
CY2014 agio Available For Sale Securities Non Current Minimum Liquidating Period
AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod
P12M
CY2014 agio Date Of Extension Of Discovery Phase
DateOfExtensionOfDiscoveryPhase
2015-06
CY2014 agio Extended Agreement Period
ExtendedAgreementPeriod
P6Y
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-27040000
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0182 pure
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3977245 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8418 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31394563 shares
CY2014Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
8411000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-12248000
CY2014Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
24000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
930000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12284000
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
5958000
CY2014Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-168000
CY2014Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
19000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12229000
CY2014Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
2143000
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
36000
CY2014Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
13000
CY2014Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
34812000
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1505000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6268000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-38723000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
20695000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12265000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
582000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17407000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
582000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1505000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2194000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3288000
CY2014Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-5958000
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
22560000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
720000
CY2014Q1 us-gaap Depreciation
Depreciation
332000
CY2014Q1 agio Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
65000
CY2014Q1 agio Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
3000
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-25585000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0171 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4559834 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
108.21
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001439222
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M17D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M28D
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7035 pure
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
238000
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS INC
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
922642 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.42
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
175034 shares
CY2015Q1 dei Trading Symbol
TradingSymbol
AGIO
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37214747 shares
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2015Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
34202000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3797000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-4957000
CY2015Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-8218000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
708000
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
207000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5195000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-172000
CY2015Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
4573000
CY2015Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
248000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4709000
CY2015Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
524000
CY2015Q1 us-gaap Reimbursement Revenue
ReimbursementRevenue
33100000
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6602000
CY2015Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
35526000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5060000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-31393000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
21225000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
39397000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
44988000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1822000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32443000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2029000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5060000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1574000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6954000
CY2015Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3841000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
84311000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2665000
CY2015Q1 us-gaap Depreciation
Depreciation
370000
CY2015Q1 agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
60000
CY2015Q1 agio Available For Sale Securities Non Current Minimum Liquidating Period
AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod
P12M
CY2015Q1 agio Number Of Development Candidates Nominated By Joint Research Committee
NumberOfDevelopmentCandidatesNominatedByJointResearchCommittee
2 Candidate
CY2015Q1 agio Revenue Recognized On Extended Agreement
RevenueRecognizedOnExtendedAgreement
0
CY2015Q1 agio Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
2000
CY2015Q1 agio Reimbursement Of Research And Development Related Party Cost
ReimbursementOfResearchAndDevelopmentRelatedPartyCost
4366000

Files In Submission

Name View Source Status
0001193125-15-181968-index-headers.html Edgar Link pending
0001193125-15-181968-index.html Edgar Link pending
0001193125-15-181968.txt Edgar Link pending
0001193125-15-181968-xbrl.zip Edgar Link pending
agio-20150331.xml Edgar Link completed
agio-20150331.xsd Edgar Link pending
agio-20150331_cal.xml Edgar Link unprocessable
agio-20150331_def.xml Edgar Link unprocessable
agio-20150331_lab.xml Edgar Link unprocessable
agio-20150331_pre.xml Edgar Link unprocessable
d917154d10q.htm Edgar Link pending
d917154dex101.htm Edgar Link pending
d917154dex311.htm Edgar Link pending
d917154dex312.htm Edgar Link pending
d917154dex321.htm Edgar Link pending
d917154dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending